CAMP4 Therapeutics Announces Nasdaq Inducement Grants to Newly Hired Employees

CAMP4 Therapeutics Corporation announced inducement grants under Nasdaq Listing Rule 5635(c)(4) for newly hired employees in February and April 2026. On April 15, 2026, the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 43,000 shares of the Company’s common stock to three newly hired employees, and on February 16, 2026, it granted a non-qualified stock option to purchase 8,000 shares to a newly hired employee.

The April inducement grants were announced on April 17, 2026. The grants have a ten-year term and an exercise price per share of $4.59, which is equal to the closing price of the company’s common stock as of the grant date. The options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of each employee’s first day of employment with the company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service through the applicable vesting dates.

The February inducement grant was announced on Feb. 20, 2026. The grant has a ten-year term and an exercise price per share of $3.85, which is equal to the closing price of the company’s common stock as of the grant date. The option will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service through the applicable vesting dates.

Each inducement grant was granted as an inducement material to entry into employment with the company and was granted pursuant to, and is subject to, the terms and conditions of an Inducement Option Award Agreement.

CAMP4 is a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases. The company said its approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled, and that its therapeutic ASO drug candidates target regulatory RNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders.